A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group
- PMID: 10554799
- DOI: 10.1046/j.1365-2141.1999.01465.x
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group
Abstract
Fluconazole is widely used as antifungal prophylaxis but it is ineffective against Aspergillus. Itraconazole has a broader spectrum of activity but the capsules give erratic bioavailability in neutropenic patients. We compared itraconazole oral solution (which has an improved pharmacokinetic profile) with fluconazole for antifungal prophylaxis. Adults with haematological malignancies receiving chemotherapy or bone marrow transplants were randomly allocated 5 mg/kg/d itraconazole (itra) solution (288 episodes) or 100 mg fluconazole suspension (flu) (293 episodes) from before the onset of neutropenia until neutrophil recovery or suspected fungal infection. Outcomes were assessed by independent reviewers unaware of the prophylaxis allocation. More proven systemic fungal infections occurred in flu (Aspergillus four, Candida tropicalis one, C. krusei one) than itra (C. albicans one) and more of these were fatal (four versus nil). This difference reached statistical significance when first study episodes were considered separately (six flu versus nil itra, P = 0.03). Significantly more deaths of presumed fungal origin occurred in flu than itra (seven versus nil, P = 0.024). There were significantly more cases of proven aspergillosis in flu than itra (six versus nil, P = 0.038, 5/6 cases were fatal) if those occurring outside the study period are included. Significantly more patients receiving flu required amphotericin B (58 v 39, P = 0.043) but this may have been affected by the fact that the study was not blinded. There were 11 proven mucosal candidal infections in flu and four in itra. Itraconazole solution and fluconazole provide effective prophylaxis against Candida but itraconazole affords greater protection against fatal aspergillosis.
Comment in
-
Itraconazole verus fluconazole in neutropenic patients.Br J Haematol. 2000 Jan;108(1):196. doi: 10.1046/j.1365-2141.2000.01858.x. Br J Haematol. 2000. PMID: 10712003 No abstract available.
Similar articles
-
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.J Antimicrob Chemother. 2006 Feb;57(2):317-25. doi: 10.1093/jac/dki440. Epub 2005 Dec 8. J Antimicrob Chemother. 2006. PMID: 16339606 Clinical Trial.
-
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.J Clin Pathol. 1999 May;52(5):376-80. doi: 10.1136/jcp.52.5.376. J Clin Pathol. 1999. PMID: 10560360 Free PMC article. Clinical Trial.
-
Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.Mycoses. 1999;42 Suppl 2:121-4. Mycoses. 1999. PMID: 10865918 Review.
-
An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.J Med Econ. 2015 May;18(5):341-8. doi: 10.3111/13696998.2014.1000460. Epub 2015 Mar 2. J Med Econ. 2015. PMID: 25524741
-
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i23-i32. doi: 10.1093/jac/dki221. J Antimicrob Chemother. 2005. PMID: 16120631 Review.
Cited by
-
Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1189-200. doi: 10.1007/s10096-015-2340-y. Epub 2015 Feb 14. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25680318 Free PMC article.
-
Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis.Antimicrob Agents Chemother. 2000 Sep;44(9):2327-32. doi: 10.1128/AAC.44.9.2327-2332.2000. Antimicrob Agents Chemother. 2000. PMID: 10952575 Free PMC article.
-
Fungal infections after hematopoietic stem cell transplantation.Int J Hematol. 2010 May;91(4):576-87. doi: 10.1007/s12185-010-0574-0. Epub 2010 May 1. Int J Hematol. 2010. PMID: 20432074 Review.
-
Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):629-38. doi: 10.1007/s10096-013-1998-2. Epub 2013 Oct 31. Eur J Clin Microbiol Infect Dis. 2014. PMID: 24173819 Free PMC article.
-
Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Haematologica. 2009 Jan;94(1):113-22. doi: 10.3324/haematol.11665. Epub 2008 Dec 9. Haematologica. 2009. PMID: 19066334 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical